CD7 CAR-T cell therapy is currently under investigation for T-ALL, with ongoing clinical trials evaluating its safety and efficacy in patients with CD7-positive malignancies.45–47 This gap in available treatments highlights the urgent need for continued research and development of effective therapies for T-ALL. Here, CD7 is linked to acute lymphoblastic leukemia.